Filter Search


Healthcare and Medical


Location Summary Deadline
France Innovative Telemedicine Devices And Services Facing The Challenges Of Medical Deserts 2026-05-23
Germany Provision Of Services Related To The Active Substance Betahistine Under An Open-house Model, As Part Of A Non-exclusive Pharmaceutical Discount Agreement. Betahistine 2026-05-23
Oman Supply Spare Parts Of Patient Monitor For Region 2026-05-23
Germany The Subject Of This Publication Is The Conclusion Of Non-exclusive Discount Agreements According To § 130a Abs. 8 Sgb V For Medicines Containing The Active Ingredient Timolol (atc Code According To Who: S01ed01). The Contract Will Be Concluded Within The 2026-05-23
Germany Conclusion Not Excluding Drug Discount Agreement. In Accordance With Section 130a Paragraph 8 Sgb V By Means Of An Open House Model For The Active Ingredient Alfacalcidol (atc Code According To Who: A11cc03) In The Dosage Form Soft Capsules 2026-05-23
Germany Open House Biologics Discount Agreements 2025-37 - Peginterferon Alfa-2a 2026-05-23
Germany The Aim Is To Conclude Discount Contracts For The Drug Natalizumab (form For Intravenous Application) In Accordance With § 130a Abs. 8 Sgb V Within The Framework Of An Open-house Procedure. The Contract Will Be Concluded With All Suitable Pharmaceutical E 2026-05-23
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph 8 Sgb V For Various Active Ingredients/combinations With The Possibility Of Conclusion At Any Time As Part Of The So-called Open House Procedure 2026-05-23
Germany The Aim Is To Conclude Discount Contracts For The Drug Natalizumab (form For Subcutaneous Injection) In Accordance With § 130a Abs. 8 Sgb V As Part Of An Open-house Procedure. The Participating Health Insurance Funds Pursue The Goal Of Concluding Discount 2026-05-24
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For Pharmaceuticals Containing The Active Ingredient Pazopanib (atc Code 2026-05-24
Whats app